Rivastigmine - Generic Drug Details

What are the generic sources for rivastigmine and what is the scope of patent protection?

Rivastigmine is the generic ingredient in three branded drugs marketed by Sandoz, Alvogen, Amneal Pharms, Breckenridge, Mylan Technologies, Yichang Humanwell, Zydus Pharms, Novartis, Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orbion Pharms, Sun Pharm, and Watson Labs, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for rivastigmine. Nine suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for rivastigmine

US Patents:	0
Tradenames:	3
Applicants:	18
NDAs:	19
Drug Master File Entries:	32
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	106
Drug Prices:	Drug price trends for rivastigmine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for rivastigmine
What excipients (inactive ingredients) are in rivastigmine?	rivastigmine excipients list
DailyMed Link:	rivastigmine at DailyMed

See drug prices for rivastigmine

Recent Clinical Trials for rivastigmine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Washington University School of Medicine	PHASE2
American Academy of Clinical Toxicology	PHASE2
Rune Skovgaard Rasmussen	PHASE2

See all rivastigmine clinical trials

Generic filers with tentative approvals for RIVASTIGMINE

Applicant	Application No.	Strength	Dosage Form
		2MG/ML	SOLUTION; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for rivastigmine

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

Medical Subject Heading (MeSH) Categories for rivastigmine

Cholinesterase Inhibitors

Neuroprotective Agents

Anatomical Therapeutic Chemical (ATC) Classes for rivastigmine

N06DA	Anticholinesterases
N06D	ANTI-DEMENTIA DRUGS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for RIVASTIGMINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXELON	Transdermal System Extended-release	rivastigmine	13.3 mg/24 hr	022083	1	2013-01-22
EXELON	Transdermal System Extended-release	rivastigmine	4.6 mg/24 hr and 9.5 mg/24 hr	022083	1	2011-04-27

US Patents and Regulatory Information for rivastigmine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Orbion Pharms	RIVASTIGMINE TARTRATE	rivastigmine tartrate	CAPSULE;ORAL	090879-002	Jun 10, 2015	AB	RX	No	No
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012	AB	RX	Yes	No
Watson Labs	RIVASTIGMINE TARTRATE	rivastigmine tartrate	CAPSULE;ORAL	077129-003	Jan 8, 2008	AB	RX	No	No
Breckenridge	RIVASTIGMINE	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	209063-002	Nov 26, 2019	AB	RX	No	No
Apotex Inc	RIVASTIGMINE TARTRATE	rivastigmine tartrate	CAPSULE;ORAL	091072-001	May 16, 2013		DISCN	No	No
Amneal Pharms	RIVASTIGMINE	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	207308-001	Jan 8, 2019	AB	RX	No	No

Expired US Patents for rivastigmine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007	4,948,807
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-001	Jul 6, 2007	6,316,023
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-001	Jul 6, 2007	4,948,807
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012	6,335,031
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-001	Jul 6, 2007	6,335,031
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007	5,602,176

EU/EMA Drug Approvals for rivastigmine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Actavis Group PTC ehf	Rivastigmine Actavis	rivastigmine	EMEA/H/C/002036Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	yes	no	no	2011-06-16
Krka, d.d., Novo mesto	Nimvastid	rivastigmine	EMEA/H/C/001029Symptomatic treatment of mild to moderately severe Alzheimer's dementia., , Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,	Authorised	yes	no	no	2009-05-11
1 A Pharma GmbH	Rivastigmine 1 A Pharma	rivastigmine	EMEA/H/C/001181Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	2009-12-11
Novartis Europharm Limited	Exelon	rivastigmine	EMEA/H/C/000169Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	1998-05-11
Novartis Europharm Limited	Prometax	rivastigmine	EMEA/H/C/000255Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	1998-12-03
Sandoz GmbH	Rivastigmine Sandoz	rivastigmine	EMEA/H/C/001183Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	2009-12-10

Rivastigmine Market Analysis and Financial Projection

Last updated: April 24, 2026

Rivastigmine: Market dynamics and financial trajectory

Rivastigmine is a symptomatic treatment for Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD). Commercial performance has been shaped by (1) patent expiries and originator generic entry, (2) payer pressure toward lower-cost options, (3) sustained demand from branded and authorized generics, and (4) differentiated product formats that support higher persistence versus many “same-molecule” substitutes.

How large is the rivastigmine opportunity and where does it sit in current demand?

Rivastigmine is sold globally in two primary AD/PDD routes, plus a transdermal option that supports adherence and reduces dosing complexity.

Core marketed formats (typical):

• Oral capsules/tablets (titrated dosing; generic-heavy in most developed markets)
• Transdermal patch (titration by patch strength; branded retention historically stronger due to formulation and switching dynamics)

Indications driving utilization:

• Alzheimer’s disease
• Parkinson’s disease dementia

Regulatory positioning (EU and US context):

• The European label includes AD and PDD uses and supports both oral and patch product lines under the rivastigmine family. The active substance is used for symptomatic cognitive impairment treatment in these dementias (EMA; EPAR for rivastigmine-containing products) [1].
• The US regulatory history for the patch includes an extended release formulation of rivastigmine delivered by transdermal system (FDA labeling) [2].

What market dynamics determine pricing and share?

Rivastigmine’s market structure is dominated by brand-to-generic transition and formulation-based differentiation.

1) Patent cliff dynamics and generic penetration

The originator of rivastigmine has experienced sustained generic entry in most mature geographies. As a result, pricing power has shifted from brand pricing toward multi-winner cost competition (authorized generics and interchangeable generics) while patch formulations often retain higher resistance to full commoditization due to:

• dosing convenience,
• adherence effects,
• pharmacy switching friction,
• and payer policies that treat patch versus oral as distinct benefit tiers.

2) Payer pressure and substitution behavior

Payer formularies typically reward:

• lowest acquisition cost for oral options, and
• preferred status (lower copays and tighter step edits) for patch when it aligns to adherence and persistence targets.

That creates two practical effects:

• Oral volume becomes more price elastic, especially after generic launches.
• Patch holds share longer when payers explicitly manage adherence outcomes or restrict oral coverage for patients already established on patch.

3) Claims, clinical practice, and adherence economics

Clinical workflows often choose rivastigmine patch for patients where adherence or tolerability makes consistent dosing difficult. That keeps rivastigmine in active-treatment portfolios even as newer AD symptom therapies compete for mindshare. The market does not expand dramatically through new clinical breakthroughs; it expands through maintenance of current patients and incremental preference for patch in suitable populations.

How does rivastigmine’s product-format mix influence financial trajectory?

Financial trajectory for rivastigmine is best understood as a function of the oral-to-patch mix and the rate of price compression in each category.

Oral

• Higher generic competition intensity
• Faster price compression
• Lower gross margin headroom

Patch

• Stronger product differentiation from formulation and delivery system
• Higher persistence among established users
• Slower price erosion when branded or authorized patch products remain payer-favored
• Potentially higher lifecycle protection from “switch-back” costs

This mix logic drives typical revenue patterns across countries:

• After generic oral entry, overall revenue growth generally flattens or declines while patch may stabilize the revenue base.
• As patch generics enter later (often with longer time-to-substitution), patch margins still compress but at a slower pace.

What does the regulatory and life-cycle record imply for commercial continuity?

Rivastigmine has a long authorization history and enduring label scope for symptomatic dementia treatment. Continuous label support lowers commercial discontinuity risk even when patent protection fades.

Evidence of sustained regulatory endorsement across Europe includes official product information for rivastigmine-containing products that maintains indication wording for AD and PDD, including dosing and administration guidance [1]. US labeling for transdermal delivery systems further anchors ongoing patch availability [2].

Where do financial results typically come under pressure?

Rivastigmine financials face predictable constraints:

1. Gross price erosion
   • Generic entry compresses net price.
   • Payer negotiations force down acquisition costs.
2. Volume replacement
   • Lost oral pricing does not fully translate into patch volume gains unless patch is actively preferred.
3. Competition from alternative symptomatic therapies
   • Rivastigmine remains part of a broader class of AD symptom medications (cholinesterase inhibitors).
   • Competition primarily shifts patient selection and adherence pathways, not elimination of symptomatic treatment demand.

Market and financial trajectory: what direction has the revenue line likely taken?

Without product-level revenue disclosures for every geography, the defensible trajectory is structural rather than speculative: originator-branded revenues decline post patent expiry; generic and authorized generics maintain total category volume but reduce value; patch mix can slow declines relative to pure oral commodity pricing.

Trajectory mechanics over the lifecycle:

• Early phase: branded pricing and moderate share leadership.
• Middle phase: originator-to-generic transition for oral reduces revenue.
• Later phase: patch persistence and delayed or partial substitution stabilizes category revenue while margins compress.
• Ongoing: payer policy and formulary position govern whether patch sustains a higher-value slice of spend.

How do formulation and switching decisions translate into financial performance?

Switching friction is where financial outcomes diverge from the “same molecule = same market” assumption.

Key drivers of reduced switching:

• Patch initiation requires titration over defined intervals.
• Patients and clinicians often remain on a stable, tolerated delivery route.
• Pharmacy and plan rules may impose restrictions that make switching less frequent.

Key drivers of increased switching:

• Lower copays for preferred oral generics.
• Automatic substitution rules and plan-sponsored interchangeability.
• Reduced patch formulary placement or higher patient out-of-pocket cost.

Competitive landscape: how is rivastigmine positioned economically?

Rivastigmine’s competitive economic posture depends on:

• clinician preference for cholinesterase inhibitors,
• payer cost containment strategy,
• and patient-specific tolerability and adherence needs.

The market tends to concentrate on lowest-cost options within the therapeutic class unless patch provides enough adherence advantage to justify higher net cost.

What do the core product labels indicate about ongoing dosing and commercialization support?

Product labeling documents show rivastigmine is positioned with established dosing and administration practices for long-term symptomatic therapy, which supports continued prescribing and replenishment patterns.

• EU product information under rivastigmine authorization provides detailed dosing approaches and administration guidance for AD and PDD use cases [1].
• US labeling for the transdermal system formalizes the patch-based extended release delivery approach and supports continuing patch commercialization [2].

These label documents matter financially because they underpin:

• stable physician prescribing behavior,
• stable patient titration and adherence support materials,
• and predictable demand through refills.

---

Key Takeaways

• Rivastigmine’s market is shaped more by patent expiry, generic pricing pressure, and payer substitution rules than by high-frequency clinical innovation.
• Oral is typically faster to commoditize and compress in net price; patch often slows revenue decline due to formulation differentiation, persistence, and payer tiering.
• Financial trajectory is consistent with a long-running lifecycle: brand value falls after generic entry; category volume remains; mix and formulary placement determine how fast revenue and margin decline.
• Regulatory continuity for AD and PDD indications supports ongoing symptomatic demand and reduces commercialization discontinuity risk [1][2].

---

FAQs

1) Is rivastigmine still sold as both oral and patch products?

Yes. Rivastigmine is marketed in oral and transdermal patch formats, with regulatory labeling supporting both approaches for symptomatic treatment in AD and PDD [1][2].

2) Why does the patch usually retain value longer than oral?

Patch use often shows higher persistence because patients and clinicians are less likely to switch stable tolerated delivery routes, and payers may keep patches favored via formularies and tiering [1][2].

3) What drives most of the revenue erosion over time?

Generic entry and payer price pressure compress net prices, especially for oral products, while patch mix can slow the rate of decline.

4) Does rivastigmine face indication-limiting regulatory change risk?

The indication scope for symptomatic treatment in AD and PDD has remained supported in regulatory product information and labeling frameworks across major jurisdictions [1].

5) What is the most important lever for future financial performance?

The oral-to-patch mix and patch formulary positioning are decisive because they control how much of total volume sits in higher-value versus commodity-priced categories.

---

References

[1] European Medicines Agency. (n.d.). Rivastigmine-containing products: EPAR/product information (indications and dosing for Alzheimer’s disease and Parkinson’s disease dementia). EMA. https://www.ema.europa.eu/ (search: “rivastigmine EPAR product information”)

[2] U.S. Food and Drug Administration. (n.d.). Rivastigmine transdermal system: Prescribing information (labeling and administration for extended release patch). FDA. https://www.accessdata.fda.gov/scripts/cder/ (search: “rivastigmine transdermal system labeling”)